Patent US4543335A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4543335A Expired / Lapsed US ⏱️ 0.0 years remaining

Device and method for the quantitative determination of heparin in mammalian blood plasma

Assignee: Bayer Corp
•
Filing: 1982-12-20
•
Granted: 1985-09-24
•
Expires: 2002-12-20
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A device for the quantitative determination of heparin in mammalian blood plasma, a method for the preparation of such device and a method for determining the plasma's heparin concentration using the device. The device, which is prepared using a freeze-drying technique, comprises a first upper layer of a carrier matrix material containing a buffer, AT-III and thrombin and a second, lower layer of a carrier matrix containing a thrombin sensitive fluorogenic or chromogenic substrate being capable of interacting with thrombin in such a manner that a time-related chemical change detectable by fluorometric or spectrophotometric means takes place when thrombin and the substrate are contacted in a suitable liquid environment.

Inventors

  • 👤 Ronald G. Sommer
  • 👤 Alfred C. Greenquist

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 17:18
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/56; G; G01; G01N; G01N2333/00; G01N2333/81; G01N2333/8107; G01N2333/811; G01N2333/8121; G01N2333/8128; G01N2333/90; G01N2333/914; G01N2333/948; G01N2333/974; G01N2400/00; G01N2400/10; G01N2400/38; G01N2400/40

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 195 words
A method for the preparation of a three layer device for the quantitative determination of heparin in mammalian blood plasma which comprises the steps of: (a) providing a first strip of carrier matrix material having incorporated therewith a buffer and a thrombin sensitive fluorogenic or chromogenic substrate, said substrate being capable of interacting with thrombin in such a manner that a time related chemical change detectable by fluorometric or spectrophotometric means takes place when thrombin and the substrate are contacted in a suitable liquid environment; (b) contacting a second strip of a carrier matrix material with a fresh, aqueous solution containing a buffer, AT-III and thrombin which solution has been maintained at a temperature below about 20° C. since before addition of the thrombin thereto to saturate the second strip with the solution; (c) removing the second strip from the solution, quick freezing it, and eliminating solvent by freeze-drying to provide a second strip containing buffer, AT-III and thrombin; (d) attaching the first strip to a strip of water impermeable material; and (e) attaching the second strip to the exposed side of the first strip to form a three-layered device suitable for the intended purpose.
Claim 2
Independent Claim 195 words
A method for the preparation of a three layer device for the quantitative determination of heparin in mammalian blood plasma which comprises the steps of: (a) providing a first strip of carrier matrix material having incorporated therewith a buffer and a thrombin sensitive fluorogenic or chromogenic substrate, said substrate being capable of interacting with thrombin in such a manner that a time related chemical change detectable by fluorometric or spectrophotometric means takes place when thrombin and the substrate are contacted in a suitable liquid environment; (b) contacting a second strip of a carrier matrix material with a fresh, aqueous solution containing a buffer, AT-III and thrombin which solution has been maintained at a temperature below about 20° C. since before addition of the thrombin thereto to saturate the second strip with the solution; (c) removing the second strip from the solution, quick freezing it, and eliminating solvent by freeze-drying to provide a second strip containing buffer, AT-III and thrombin; (d) attaching the first strip to a strip of water impermeable material; and (e) attaching the second strip to the exposed side of the first strip to form a three-layered device suitable for the intended purpose.
Claim 3
Dependent Claim 21 words
The method of claim 1 wherein the solution containing AT-III and thrombin is maintained at a temperature of below 5° C.
Claim 4
Dependent Claim 15 words
The method of claim 1 wheren the buffer is tris(hydroxymethyl)-aminomethane; N,N-bis-(2-hydroxymethyl)glycine or tris(hydroxymethyl)methyl aminopropanesulfonic acid.
Claim 5
Dependent Claim 26 words
The method of claim 1 wherein the substrate is H-D-phe-pip-arg-pNA and the buffer is capable of maintaining the pH in the range of 8.0 to 8.5.
Claim 6
Dependent Claim 25 words
The method of claim 1 wherein the ratio of thrombin to AT-III in the aqueous solution is greater than 0.05 NIH unit thrombin:1 μg AT-III.
Claim 7
Dependent Claim 23 words
The method of claim 5 wherein the ratio is from 0.2 NIH unit thrombin:1 μg AT-III to 0.5 NIH unit thrombin-1 μg AT-III.
Claim 8
Dependent Claim 26 words
The method of claim 1 wherein the carrier matrix of either or both the first strip and second strip is a film or a bibulous material.
Claim 9
Dependent Claim 14 words
The method of claim 7 wherein the film is formed of gelatin or agarose.
Claim 10
Dependent Claim 22 words
The method of claim 7, the bibulous material is paper, cellulose, wood, a synthetic resin fleece or a woven or nonwoven fabric.
Claim 11
Dependent Claim 116 words
A three layer test device suitable for the quantitative determination of heparin in mammalian blood plasma which comprises: i. a first upper layer of a carrier matrix material containing a buffer, AT-III and thrombin; ii. a second layer adjacent to and in contact with the first layer said second layer comprising a carrier matrix containing a thrombin sensitive fluorogenic or chromogenic substrate and a buffer said substrate being capable of interacting with thrombin in such a manner that a time-related chemical change detectable by fluorometric or spectrophotometric means takes place when thrombin and the substrate are contacted in a suitable liquid environment; and iii. a third layer of a water impermeable material beneath the second layer.
Claim 12
Dependent Claim 116 words
A three layer test device suitable for the quantitative determination of heparin in mammalian blood plasma which comprises: i. a first upper layer of a carrier matrix material containing a buffer, AT-III and thrombin; ii. a second layer adjacent to and in contact with the first layer said second layer comprising a carrier matrix containing a thrombin sensitive fluorogenic or chromogenic substrate and a buffer said substrate being capable of interacting with thrombin in such a manner that a time-related chemical change detectable by fluorometric or spectrophotometric means takes place when thrombin and the substrate are contacted in a suitable liquid environment; and iii. a third layer of a water impermeable material beneath the second layer.
Claim 13
Dependent Claim 27 words
The test device of claim 10 wherein the substrate is H-D-phe-pip-arg-pNA and the buffer is capable of maintaining the pH in the range of 8.0 to 8.5.
Claim 14
Dependent Claim 27 words
The test device of claim 10 wherein the carrier matrix of either or both the first layer and second layer is a film or a bibulous material.
Claim 15
Dependent Claim 18 words
The test device of claim 12 wherein the carrier matrix is a film formed of gelatin or agarose.
Claim 16
Dependent Claim 29 words
The test device of claim 12 wherein the carrier matrix is a bibulous material selected from paper, cellulose, wood, a synthetic resin fleece or a woven or nonwoven fabric.
Claim 17
Dependent Claim 103 words
A method for the quantitative determination of heparin in mammalian blood plasma which comprises: (a) contacting mammalian blood plasma with the device described in claim 10; (b) monitoring any chemical change in the substrate by reflectance spectrofluorometric or reflectance spectrophotometric means repeatedly over a period of time to obtain at least 2 spectrofluorometric or spectrophotometric values as a function of time; and (c) comparing the relationship between the values obtained in step (b) with values obtained in a like-manner using plasma samples containing known amounts of heparin and using such comparison to determine the concentration of heparin in the plasma sample being tested.

References Cited (Backward Citations)

US30267A Cited
US3891507A Cited
USRE30267E Cited
US4181500A Cited
US4234682A Cited
US4442204A Cited
US4390343A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-09-23 1989-03-25 1989-09-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-09-23 1993-03-25 1993-09-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-09-23 1997-03-25 1997-09-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag